
|Videos|April 6, 2016
How Renal Function and Comorbidities Affect Dosing for NOACs
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient's renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
Advertisement
John Fanikos, RPh, MBA, director of pharmacy at Brigham and Women's Hospital, discusses how a patient’s renal function and comorbidities affect dosing regimens for novel oral anticoagulants.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
2
The Side Door We Could Close: A Pharmacy Perspective on Menopause, Access, and the Leadership Pipeline
3
Tirzepatide Cuts MACE Risk in Diabetes With Heart Disease
4
Study Reveals a Widening Gap Between Buprenorphine Prescribing and Dispensing
5



































































































